A Phase 4 interventional study of iGlarLixi (insulin glargine/lixisenatide) and Gla-100 (insulin glargine) in Type 2 Diabetes (T2D), sponsored by Sanofi. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 28th largest by planned enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2024, is one of 103 in phase 4, and was the 173rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 678 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 30th largest by planned enrollment of the 178 interventional ones that give a count, is one of 2 that started in 2024, is one of 75 in phase 4, and was the 185th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR from CGM device in Chinese insulin naïve patients with T2D inadequately controlled with OADs. At the end of the screening period, eligible participants will be randomized to one of two treatment groups (iGlarLixi or Gla-100 group). The randomization (1:1) will be stratified by values of HbA1c at screening (\<8.0%, ≥8.0%), and background treatment (metformin only, metformin+SGLT-2i).
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive iGlarLixi once daily for 20 weeks. iGlarLixi is to be initiated with the starting daily dose of 5-10 dose steps on Visit 4 (Day 1) and will be titrated according to fasting SMBG to achieve glycemic target of ≥80 and ≤110 mg/dL.
Drug: iGlarLixi (insulin glargine/lixisenatide)
Participants will receive Gla-100 once daily for 20 weeks. Gla-100 is to be initiated with the starting daily dose of 5-10 U on Visit 4 (Day 1) and will be titrated according to fasting SMBG to achieve and maintain same glycemic target of ≥80 and ≤110 mg/dL.
Drug: Gla-100 (insulin glargine)
Drug pages: Insulin Glargine · Lixisenatide
iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector. There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day: \- iGlarLixi must not be mixed with other insulins nor diluted.
Also known as: SOLIQUA®
Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
Also known as: LANTUS®
Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]
Superiority of mean change in the percentage of TIR \[3.9-10.0 mmol/L (70-180 mg/dL)\] from baseline to Week 20 of iGlarLixi vs Gla-100
Time frame: from baseline to Week 20
2a Proportion (%) of participants achieving TIR target as >70%
Time frame: Week 20
2b Change (%) in TAR >10.0 mmol/L (>180 mg/dL)
Time frame: from baseline to Week 20
2c Change (mg/dL) in mean daily glucose
Time frame: from baseline to Week 20
2d Proportion (%) of participants achieving composite target of TIR as >70% [3.9-10.0 mmol/L (70-180 mg/dL)] with TAR as <25% [>10.0 mmol/L (>180 mg/dL)] with TBR as <4% [<3.9 mmol/L (<70 m)/dL)]
Time frame: Week 20
Change (%) in coefficient of variation (CV)
Time frame: from baseline to Week 20
Change (%) in the percentage of time in tight range (TITR) [3.9-7.8 mmol/L (70-140 mg/dL)]
Time frame: from baseline to Week 20
Proportion (%) of participants achieving TITR [3.9-7.8 mmol/L (70-140 mg/dL)] >50%
Time frame: Week 20
Proportion (%) of participants achieving ≥5% TIR improvement
Time frame: from baseline to Week 20
Proportion (%) of participants achieving ≥10% TIR improvement
Time frame: from baseline to Week 20
Change (%) in TAR >13.9 mmol/L (>250 mg/dL)
Time frame: from baseline to Week 20
Change (%) in time below range (TBR)
* \<3.9 mmol/L (\<70 mg/dL), including \<3.0 mmol/L (\<54 mg/dL) * \<3.0 mmol/L (\<54 mg/dL) * \<3.9 mmol/L (\<70 mg/dL), including \<3.0 mmol/L (\<54 mg/dL) in nocturnal (00:00 h-05:59 h) time * \<3.0 mmol/L (\<54 mg/dL) in nocturnal (00:00 h-05:59 h) time
Time frame: from baseline to Week 20
Change in mean glucose standard deviation (SD)
Time frame: from baseline to Week 20
Change (%) in glucose management indicator (GMI)
Time frame: from baseline to Week 20
Proportion (%) of participants achieving CV <36%
Time frame: Week 20
Proportion (%) of participants achieving CV <32%
Time frame: Week 20
Change (%) in HbA1c
Time frame: from baseline to Week 12 and Week 20
Proportion (%) of participants achieving HbA1c <7%
Time frame: Week 12 and Week 20
Proportion (%) of participants achieving HbA1c <7% without documented hypoglycemia
documented hypoglycemia (defined as ADA Level 1, 2 or 3)
Time frame: Week 20
Proportion (%) of participants achieving HbA1c <7% without body weight gain
body weight gain (≥5% compared to baseline)
Time frame: Week 20
Proportion (%) of participants achieving HbA1c <7% without documented hypoglycemia and without body weight gain
documented hypoglycemia (defined as ADA Level 1, 2 or 3)
Time frame: Week 20
Change (mmol/L) in fasting plasma glucose (FPG), 2-hour postprandial glucose (PPG)
Time frame: from baseline to Week 12 and Week 20
Change (nmol/L) in fasting C-peptide and post-prandial C-peptide
Time frame: from baseline to Week 12 and Week 20
Change (U and U/Kg) in insulin dose
Time frame: from baseline to Week 20
Change (kg) in body weight
Time frame: from baseline to Week 20
Change (%) in TIR [3.9-10.0 mmol/L (70-180 mg/dL)], TAR [>10.0 mmol/L (>180 mg/dL)] and TBR [3.0 mmol/L (<54 mg/dL)] for specific time blocks (6 am-12 pm, 12 pm-6 pm, 6 pm-12 am, and 12 am-6 am)
Time frame: from baseline to Week 20
Change in diabetes medication treatment satisfaction scores (total score and by subscales), using the treatment-related impact measure diabetes (TRIM-D) questionnaire
Time frame: from baseline to Week 20
AE, serious adverse event (SAE), and adverse event of special interest (AESI)
Time frame: from screening to week 21
Overall hypoglycemia events and rates
Time frame: from screening to week 21
Nocturnal (00:00 h-05:59 h) hypoglycemia events and rates
Time frame: from baseline to Week 20
Confirmed hypoglycemia (ADA Level 1, 2 and 3)
* ADA Level 1: Measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L) * ADA Level 2: Measurable glucose concentration \<54 mg/dL (3.0 mmol/L) that needs immediate action * ADA Level 3: Severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery
Time frame: from baseline to Week 20
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 21 months after the start.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 21 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Lixisenatide